WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Pharmacovigilance of Immunotherapy Drug used in Oncology

Narawade Mrunal Sandeep*, Varpe Mahendra Rajendra[1], Deshmukh Amol Sampat[2], Divate Vaishnavi Haribhau[3],Kale Gauri Balshiram[4],Gulve Rushikesh Mothyabhau[5]

*Assistant Professor, Shri Swami Samarth Institutes, Malwadi (Bota), Maharashtra, India[1,2]

[1-5]Student, B. Pharmacy, Shri Swami Samarth Institutes, Malwadi (Bota), Maharashtra[3,4,5]

Email :- mrunalnarawade12@gmail.com

Abstract:

Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to recognize and destroy cancer cells. Therapies such as immune checkpoint inhibitors, CAR-T cell therapy, cytokines, and cancer vaccines have shown remarkable clinical benefits across various malignancies. However, these treatments are associated with unique and sometimes severe immune-related adverse events (irAEs) that differ from toxicities seen with traditional chemotherapy. Therefore, pharmacovigilance plays a crucial role in ensuring the safe and effective use of immunotherapy drugs in oncology. Continuous monitoring, detection, assessment, and reporting of adverse events are essential to understand the long-term safety profile and risk–benefit balance of these agents. Key pharmacovigilance challenges include delayed onset of adverse reactions, complex mechanisms of toxicity, underreporting, and the need for harmonized global regulatory frameworks. The objective of this review is to highlight the significance of pharmacovigilance in cancer immunotherapy, discuss common safety concerns, and outline strategies for effective risk management and patient safety enhancement.

Keywords: Immunotherapy, Pharmacovigilance, Immune-related Adverse Events(irAEs), Oncology**.**

1.Introduction:

Immunotherapy has transformed modern cancer treatment by empowering the immune system to fight malignant cells, offering renewed hope for patients with advanced or resistant tumors. In contrast to chemotherapy or radiation, which act directly on cancer cells, immunotherapeutic agents stimulate immune responses to recognize and destroy them. Treatments such as immune checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies have shown remarkable improvements in survival rates across several cancer types.

Despite these benefits, immunotherapy presents distinct safety challenges compared to traditional cancer therapies. Because of immune system overactivation, patients may experience immune-related adverse events (irAEs) that can affect vital organs including the skin, lungs, liver, and endocrine glands. These reactions may develop long after treatment begins, complicating diagnosis and management.

To address these concerns, a strong pharmacovigilance framework is crucial. Ongoing surveillance, early identification, and appropriate management of adverse effects are essential to ensure patient safety and maintain a favorable balance between therapeutic benefit and risk. Reinforcing pharmacovigilance practices in immuno-oncology is key to improving treatment safety and optimizing outcomes in cancer care.

2.Overview of Immunotherapy in Oncology:

2.1. Classes of Immunotherapeutic Agents:

Classes of Immunotherapeutic Agents Used in Oncology Immunotherapeutic agents used in cancer treatment can be broadly classified into the following major categories:

1. Immune Checkpoint Inhibitors (ICIs): These drugs block inhibitory pathways (checkpoints) on immune cells, thereby enhancing T-cell activity against cancer cells.

Examples:

PD-1 inhibitors: Nivolumab, Pembrolizumab

PD-L1 inhibitors: Atezolizumab, Durvalumab, Avelumab

CTLA-4 inhibitor: Ipilimumab

2. Cytokine-Based Therapies:

Cytokines are immune-signaling proteins that boost immune cell proliferation and activity.

Examples: Interleukin-2 (Aldesleukin), Interferon-alpha

3. Monoclonal Antibodies (mAbs):

These are laboratory-made antibodies designed to target specific antigens on cancer cells, leading to immune-mediated destruction.

Examples: Rituximab (CD20), Trastuzumab (HER2), Cetuximab (EGFR)

4. Cancer Vaccines:

These vaccines stimulate the immune system to recognize tumour-specific antigens and mount a targeted immune response.

Examples: Sipuleucel-T (for prostate cancer), HPV vaccine (for cervical cancer prevention)

5. Adoptive Cell Therapies (ACT):

In this approach, immune cells are collected from the patient, genetically modified or expanded, and reinfused to attack tumour cells.

Examples: CAR-T cell therapy (Tisagenlecleucel, Axicabtagene ciloleucel), Tumor-Infiltrating Lymphocyte (TIL) therapy

6. Oncolytic Virus Therapy:

These therapies use genetically modified viruses that selectively infect and kill cancer cells while stimulating an anti-tumor immune response.

Example: Talimogene laherparepvec (T-VEC)

2.2 Mechanism of Action and Implication for Safety:

Immunotherapy works by modulating the immune system to recognize and destroy cancer cells more effectively. Unlike chemotherapy, which directly kills tumor cells, immunotherapeutic agents enhance or restore the natural immune response against cancer.

Immune Checkpoint Inhibitors (ICIs): These drugs block inhibitory pathways such as PD-1/PD-L1 and CTLA-4 that normally suppress T-cell activity. By releasing these “brakes,” ICIs activate cytotoxic T-cells to attack tumor cells.

Safety implication: Overactivation of the immune system can lead to immune-related adverse events (irAEs) affecting the skin, liver, lungs, gut, and endocrine organs.

CAR-T Cell Therapy: In this method, a patient’s T-cells are genetically engineered to express chimeric antigen receptors (CARs) that specifically target tumour antigens.

Safety implication: It can cause cytokine release syndrome (CRS) and neurotoxicity due to massive immune activation.

Cytokine Therapy: Agents like interleukins and interferons enhance immune cell proliferation and activity.

Safety implication: May lead to systemic inflammatory responses, such as fever, fatigue, or hypotension

Because these therapies act by boosting immune function, the same mechanisms that attack cancer can also damage healthy tissues. Therefore, pharmacovigilance is essential to identify, monitor, and manage these unpredictable and sometimes delayed adverse reactions, ensuring a proper balance between efficacy and safety in cancer immunotherapy.

3.Pharmacovigilance in Oncology:

3.1 Definition and Scope in Pharmacovigilance:

Definition:

According to the World Health Organization (WHO), pharmacovigilance is "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem." In oncology, it focuses on ensuring the safe and effective use of anticancer drugs, including new immunotherapeutic agents.

Scope:

Pharmacovigilance in oncology covers the monitoring, evaluation, and reporting of adverse drug reactions (ADRs) associated with cancer treatments. It includes both pre-approval clinical trials and post-marketing surveillance, aiming to identify rare, long-term, or delayed toxicities that may not appear during initial testing.

Objectives in Oncology:

- To detect and evaluate adverse reactions related to anticancer drugs, especially immune-related events.
- To ensure patient safety by identifying risks early and implementing preventive measures.
- To update treatment guidelines and labeling based on real-world safety data.
- To enhance rational use of cancer medicines through evidence-based safety information.
- To support regulatory decisions for continued safe use or modification of drug indications.

3.2 Challenges in Oncology Pharmacovigilance:

Pharmacovigilance in oncology encounters several distinctive difficulties due to the complex nature of cancer treatment and patient diversity. One major challenge is polypharmacy, as cancer patients are often prescribed numerous drugs such as chemotherapy, immunotherapy, steroids, and supportive agents. This increases the likelihood of drug interactions and complicates the identification of the specific drug responsible for an adverse event. Another issue is the delayed onset of adverse reactions; immune-related toxicities may appear long after therapy has ended, making timely detection and causality assessment difficult.

Underreporting of side effects is also common, often due to limited awareness, lack of time, or the perception that adverse effects are inevitable parts of cancer therapy. Additionally, the complex biology of cancer and patient variability, including differences in genetics, tumor characteristics, and immune response, make predicting adverse events challenging. Moreover, clinical trial data are limited because participants are usually selected and monitored under controlled conditions, meaning rare or long-term effects often become apparent only after the drug reaches the wider population.

4.Safety Profiles and Adverse Events of Immunotherapy:

Immunotherapy has revolutionized cancer care by improving patient outcomes, but it is also linked to specific immune-related adverse events (irAEs) caused by overstimulation of the immune response. Unlike the toxicities seen with chemotherapy, irAEs can involve multiple organ systems and differ widely in timing, intensity, and duration. These effects are evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), which categorizes them from Grade 1 (mild) to Grade 5 (death-related) based on severity.

The most frequent irAEs include skin disorders such as rash and itching, gastrointestinal problems like diarrhoea and colitis, endocrine dysfunctions including thyroiditis and adrenal insufficiency, and liver inflammation such as hepatitis. Other notable effects are pneumonitis and musculoskeletal pain. While many irAEs are mild or moderate and respond to corticosteroids or immunosuppressive drugs, some can become severe or fatal, such as myocarditis, severe pneumonitis, or neurological complications.

Thus, maintaining a strong pharmacovigilance framework is vital to promptly identify, monitor, and manage these adverse effects. Ongoing safety evaluation helps prevent serious complications, supports clinical decision-making, and ensures the safe use of immunotherapy in oncology.

Delayed and Long-Term Effects of Immunotherapy:

Immunotherapy, while highly effective in treating various cancers, can lead to delayed and long-term adverse effects due to its prolonged impact on the immune system. Unlike traditional therapies, the immune activation induced by immunotherapeutic agents may persist even after treatment discontinuation, resulting in autoimmune and irreversible effects. These include chronic conditions such as hypothyroidism, adrenal insufficiency, or type 1 diabetes caused by sustained immune-mediated damage to endocrine organs. In some patients, persistent inflammation may lead to chronic toxicity affecting the lungs, liver, or joints, manifesting as pneumonitis, hepatitis, or arthritis long after therapy has ended. Additionally, the long latency period of some immune-related adverse events (irAEs) makes early detection challenging, emphasizing the need for long-term follow-up and continuous pharmacovigilance.

Understanding these delayed toxicities is essential to balance treatment efficacy with long-term safety and to develop appropriate management strategies for cancer survivors receiving immunotherapy.

5.Pharmacovigilance Strategies for Immunotherapy:

Strong pharmacovigilance strategies are vital for tracking and managing the unique safety concerns associated with immunotherapy in cancer treatment. The spontaneous reporting system is a key component, allowing healthcare professionals and patients to submit reports of suspected adverse drug reactions to monitoring authorities. These reports are compiled in national and global safety databases such as WHO's VigiBase, the U.S. FDA Adverse Event Reporting System (FAERS), and the European Medicines Agency's EudraVigilance. Through these platforms, safety signals can be detected, evaluated, and used to update risk information. Nevertheless, spontaneous reporting has inherent limitations, including underreporting, incomplete case details, and difficulty identifying rare or delayed immune-related adverse events (irAEs) linked to immunotherapy. To overcome these gaps, pharmacovigilance systems must combine active surveillance, patient registries, and real-world evidence to enhance early detection, improve data quality, and ensure safer clinical use of immunotherapeutic agents.

Active Surveillance and Registries in Immunotherapy Pharmacovigilance: Beyond spontaneous reporting systems, active surveillance and patient registries are essential tools for strengthening pharmacovigilance in immunotherapy. Active surveillance focuses on proactively gathering and analyzing safety data from patients receiving immunotherapeutic agents, allowing for earlier detection and better characterization of adverse effects. Post-marketing (Phase IV) studies help evaluate the long-term safety, real-world efficacy, and rare immune-related adverse events (irAEs) that may not appear during clinical trials. Additionally, cancer immunotherapy registries compile information from patients treated with checkpoint inhibitors, CAR-T cells, and monoclonal antibodies, offering critical insights into delayed toxicities and treatment outcomes. These systems together promote continuous monitoring, improve understanding of risk factors, and guide the development of evidence-based strategies to ensure the safe, effective, and sustainable use of immunotherapy in oncology.

Signal Detection and Risk Management in Immunotherapy Pharmacovigilance:

In pharmacovigilance for immunotherapy drugs, signal detection and risk management are vital to maintaining patient safety. The process of signal detection aims to recognize emerging safety concerns by analyzing large databases of adverse event reports through statistical tools like disproportionality analysis, which includes methods such as the proportional reporting ratio and reporting odds ratio. These analyses help identify abnormal reporting trends or clusters of specific immune-related adverse events (irAEs).

After a safety signal is confirmed, risk management actions are introduced to reduce or prevent patient harm. These may include risk minimization measures such as revising drug labeling, issuing safety communications, providing clinical guidance, and training healthcare professionals on early recognition and management of irAEs. Furthermore, regulatory authorities may mandate Risk Evaluation and Mitigation Strategies (REMS) to ensure that the therapeutic advantages of immunotherapy outweigh potential risks through controlled distribution, ongoing monitoring, and patient education. Collectively, these mechanisms support early detection, prevention, and effective control of immunotherapy-related safety concerns in oncology.Beyond spontaneous reporting systems, active surveillance and patient registries are essential tools for strengthening pharmacovigilance in immunotherapy. Active surveillance focuses on proactively gathering and analyzing safety data from patients receiving immunotherapeutic agents, allowing for earlier detection and better characterization of adverse effects. Post-marketing (Phase IV) studies help evaluate the long-term safety, real-world efficacy, and rare immune-related adverse events (irAEs) that may not appear during clinical trials. Additionally, cancer immunotherapy registries compile information from patients treated with checkpoint inhibitors, CAR-T cells, and monoclonal antibodies, offering critical insights into delayed toxicities and treatment outcomes.

These systems together promote continuous monitoring, improve understanding of risk factors, and guide the development of evidence-based strategies to ensure the safe, effective, and sustainable use of immunotherapy in oncology.

6.Role of Healthcare Professionals and Patients in Pharmacovigilance:

The participation of healthcare professionals and patients in pharmacovigilance for immunotherapy drugs used in oncology is vital to promote patient safety and enhance treatment effectiveness. Immunotherapy agents such as immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal

antibodies often cause unpredictable and immune-related side effects. Hence, identifying and reporting these reactions at an early stage is crucial to avoid severe complications. Healthcare workers—like oncologists, pharmacists, and nurses-play a key role in continuously observing patients, detecting any warning signs of toxicity, recording adverse events accurately, and informing pharmacovigilance or regulatory bodies. Prompt detection and reporting enable timely clinical decisions such as adjusting doses or pausing treatment, ultimately improving patient outcomes.

Training and awareness are equally important aspects of pharmacovigilance. Through regular workshops, continuing medical education sessions, and updated clinical guidelines, healthcare providers can strengthen their ability to identify and manage immunotherapy-related toxicities effectively. Similarly, patients should be educated about potential side effects and encouraged to report any unusual symptoms, which helps them become active contributors to their own safety.

In addition, the integration of digital technologies has significantly enhanced pharmacovigilance activities. Tools such as electronic health records (EHRs), mobile reporting apps, online submission portals, and AI-driven data systems allow real-time surveillance and faster information exchange between healthcare providers and regulatory agencies. These technological tools make reporting more efficient and accurate. Altogether, collaboration between trained healthcare professionals and informed patients—supported by modern digital systems—creates a strong pharmacovigilance framework to ensure the safe and effective use of immunotherapy in cancer care.

7.Regulatory Landscape:

The global regulatory framework for pharmacovigilance of immunotherapy drugs used in oncology is governed by major health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). These organizations have established detailed guidelines to monitor the safety and effectiveness of immunotherapy products throughout their development and post-approval stages. The FDA focuses on post-marketing safety through systems like the FDA Adverse Event Reporting System (FAERS) and requires manufacturers to provide Periodic Safety Update Reports (PSURs) and implement Risk Evaluation and Mitigation Strategies (REMS) where needed. The EMA, operating under the Good Pharmacovigilance Practices (GVP) framework, mandates Risk Management Plans (RMPs), PSUR submissions, and continuous assessment of the benefit–risk balance across the European Union. The WHO, through the Uppsala Monitoring Centre (UMC), facilitates global cooperation by encouraging data exchange, signal detection, and harmonization of pharmacovigilance standards among member nations.

Although the core goals of these agencies are similar, regional variations exist. The FDA generally employs a product-centered model emphasizing manufacturer accountability, whereas the EMA uses a coordinated approach involving multiple EU member states. In contrast, developing nations often face challenges such as limited resources and underreporting of adverse events, making WHO's role in strengthening local pharmacovigilance capacity essential.

Immunotherapy drugs frequently receive conditional or accelerated approvals due to their potential in treating severe or life-threatening cancers. These approvals are linked to strict post-marketing requirements, including Phase IV clinical studies, extended safety tracking, and real-world evidence collection to validate long-term safety and efficacy. Such ongoing monitoring is a cornerstone of pharmacovigilance, ensuring that newly identified risks are promptly detected and managed. Collectively, the coordinated efforts of the FDA, EMA, WHO, and national authorities establish a strong global system that balances patient safety with continued innovation in cancer immunotherapy

8.Case Studies /Recent Safety Signals:

In recent years, pharmacovigilance has played a crucial role in detecting and managing safety concerns linked to immunotherapy drugs in cancer treatment. Immune checkpoint inhibitors such as nivolumab, pembrolizumab, ipilimumab, and atezolizumab have significantly advanced oncology care, yet they are also associated with various immune-related adverse events (irAEs). One important safety signal identified through post-marketing surveillance was severe immune-mediated myocarditis in patients receiving a combination of nivolumab and ipilimumab. Due to the seriousness of this reaction, both the FDA and EMA revised the drug labels to include stricter warnings about cardiac monitoring and early intervention. Similarly, pembrolizumab was linked to immune-mediated pneumonitis and colitis, leading to updated prescribing information that highlights the importance of early recognition, corticosteroid treatment, and therapy interruption when necessary.

Further pharmacovigilance assessments revealed that atezolizumab and durvalumab could induce hepatitis and endocrine disorders. These findings resulted in improved risk management plans (RMPs) and greater awareness among healthcare professionals regarding liver and thyroid function monitoring. In some cases, post-marketing data have even led to restricted indications or withdrawal of conditional approvals. For example, nivolumab and pembrolizumab lost their accelerated approvals for certain urothelial and small-cell lung cancer indications after confirmatory studies did not show sufficient survival benefits.

Overall, these examples emphasize the importance of ongoing safety surveillance, the use of real-world evidence, and coordinated regulatory actions in identifying and addressing emerging safety issues related to immunotherapy. Measures such as label revisions, updated clinical protocols, and post-approval research highlight how pharmacovigilance ensures that the benefits of innovative cancer therapies continue to outweigh their potential risks.

9.Future Direction in Pharmacovigilance for Immunotherapies:

The future of pharmacovigilance in oncology immunotherapies is moving toward advanced, personalized, and data-driven systems. The use of artificial intelligence (AI) and machine learning (ML) is expected to greatly enhance signal detection by analyzing vast and diverse data sources such as electronic health records, clinical registries, spontaneous adverse event reports, and even patient-generated or social media data. These technologies can identify rare or complex safety signals much earlier than conventional methods. Additionally, the incorporation of real-world data (RWD) and real-world evidence (RWE)—including data from EHRs, insurance claims, patient registries, wearable health devices, and patient-reported outcomes—will enable continuous and comprehensive safety surveillance that better mirrors everyday clinical practice and diverse patient populations.

Emerging biomarkers and companion diagnostic tools, such as immune activation markers, genetic indicators, and cytokine profiles, are anticipated to help predict patients who are more susceptible to certain immune-related adverse events (irAEs). This knowledge will allow clinicians to implement preventive strategies and monitor high-risk patients more effectively. These innovations will pave the way for personalized pharmacovigilance, where monitoring and follow-up are tailored to individual patient profiles through adaptive risk-based plans, targeted laboratory testing, and customised patient education to improve early detection and management of adverse effects. However, realizing this vision will require strong frameworks for data standardization, system interoperability, and ethical data governance. Clear regulatory guidance for the use of AI and real-world evidence in pharmacovigilance decision-making, along with collaboration among healthcare professionals, regulators, pharmaceutical companies, and patients, will be essential to transform predictive insights into safer, patient-centered cancer care.

10. Conclusion:

Immunotherapy has transformed cancer treatment by offering durable and targeted therapeutic benefits, but it also presents unique immune-related safety challenges that require strong and continuous pharmacovigilance. Ongoing monitoring, timely detection of adverse events, active reporting by healthcare professionals and patients, and coordinated regulatory oversight are essential to ensure safe and effective use of these therapies. As immune-related adverse events can be unpredictable, delayed, and sometimes severe, integrating real-world evidence, advanced surveillance systems, and emerging technologies such as AI will play a crucial role in improving early signal detection and risk management. Strengthening global pharmacovigilance practices will ultimately help maintain the benefit–risk balance of immunotherapies and support safer, more personalized cancer care in the future.

Reference:

1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-68.

2. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28(suppl_4:iv119-42.

3. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-68.

4. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: NCCN guidelines insights. J Natl Compr Canc Netw. 2017;15(7):712-36.

5. Mahadevan NR, Atkins MB, Beer TM, et al. Pharmacovigilance of immune checkpoint inhibitors: Challenges and opportunities. Clin Cancer Res. 2019;25(5):1631-7.

6. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86-104.

7. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.

8. Touat M, Talmasov D, Hollebecque A, Knauss S, Besse B, Levy R, et al. Immune checkpoint inhibitor-related adverse events: A pharmacovigilance perspective. Lancet Oncol. 2021;22(6):e303-13.

9. Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721-8.

10. Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;36:k4226.